home / stock / phat / phat news

PHAT News and Press, Phathom Pharmaceuticals Inc. From 10/18/21

Stock Information
Company Name: Phathom Pharmaceuticals Inc.
Stock Symbol: PHAT
Market: NYSE
Website: phathompharma.com
Menu
PHAT PHAT Quote PHAT Short PHAT News PHAT Articles PHAT Message Board
Get PHAT Alerts

News, Short Squeeze, Breakout and More Instantly...
PHAT - IONS, BTCS and NXTD among mid-day movers

Gainers: ION Geophysical (NYSE:IO) +42%. Valneva (NASDAQ:VALN) +33%. Progenity (NASDAQ:PROG) +31%. MeiraGTx (NASDAQ:MGTX) +30%. BTCS (NASDAQ:BTCS) +22%. Peabody Energy (NYSE:BTU) +20%. Evolving Systems (NASDAQ:EVOL) +18%. InMed (NASDAQ:INM) +16%. TORM (NASDAQ:TRMD) +17%. Aerovate (NASDAQ:AVTE...
PHAT - Valneva SE, MeiraGTx leads healthcare gainers; Revance Therapeutics, Omeros aming major losers

Gainers: Valneva SE VALN +33%, MeiraGTx (NASDAQ:MGTX) +22%, Adamis Pharmaceuticals ADMP +20%, Aerovate Therapeutics AVTE +18%, Progenity (NASDAQ:PROG) +16%. Losers: Revance Therapeutics RVNC -42%, Omeros OMER -25%, MannKind MNKD...

PHAT - Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID ® ), a proton pump inhibitor (PPI) Vonopr...

PHAT - Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)

Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID ® ) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.&#x...
PHAT - Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million t...

PHAT - Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two new drug a...

PHAT - Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and CEO...
PHAT - Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021 Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling ahead of schedule with topline data now expected in the first quarter of 2022 ...

PHAT - Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and fo...

PHAT - Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phathom’s ...
Previous 10 Next 10